Active-ingredient Dossier
Ustekinumab
Active-ingredient Dossier for Ustekinumab (interleukin inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: STELARA
- Brand: STEQEYMA
- Brand: WEZLANA
- Brand: EPYZTEK
- Brand: UTEKNIX
- Brand: AJEMNYE
- Therapeutic area: Immunology
What is
Ustekinumab Ustekinumab is an interleukin inhibitor.
Australian brands containing
Ustekinumab — STELARA — STEQEYMA — UTEKNIX — EPYZTEK — WEZLANA — AJEMNYE — SETRELVO — YESINTEK
Therapeutic areas
Ustekinumab is registered in immunology, with 8 brands containing the ingredient on the ARTG.
Sponsor landscape
Ustekinumab is marketed by six sponsors: Amgen, Janssen-Cilag, Samsung Bioepis AU, Celltrion Healthcare, Cipla, and Maxx Pharma.
PBS and regulatory activity
Two brands containing ustekinumab have PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2024–25 financial year, PBS expenditure on ustekinumab was $517,329,068.73 across 73,601 scripts. The latest PBAC outcome was recorded on 1 March 2025, and the latest AusPAR was published on 20 January 2025.